Achilles Therapeutics plc (ACHL) Research

Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.

Market snapshot

Symbol
ACHL
Price
$1.48
Day change
+0.68%
Market cap
$60.8M
P/E ratio
-0.85x
52-week range
0.63-1.51
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$2.00

Peer companies

  • AlloVir, Inc. (ALVR)
  • Heat Biologics, Inc. (HTBX)
  • Kronos Bio, Inc. (KRON)
  • Quince Therapeutics, Inc. (QNCX)
  • Rein Therapeutics Inc. (RNTX)
  • Reneo Pharmaceuticals, Inc. (RPHM)
  • Sigilon Therapeutics, Inc. (SGTX)
  • Surface Oncology, Inc. (SURF)

Open Achilles Therapeutics plc (ACHL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.